Literature DB >> 22921234

Surgical experience with aggressive aortic pathologic process in Loeys-Dietz syndrome.

Yutaka Iba1, Kenji Minatoya, Hitoshi Matsuda, Hiroaki Sasaki, Hiroshi Tanaka, Hiroko Morisaki, Takayuki Morisaki, Junjiro Kobayashi, Hitoshi Ogino.   

Abstract

BACKGROUND: Loeys-Dietz syndrome (LDS) is a recently recognized connective tissue disorder (CTD) caused by mutations in transforming growth factor-beta receptor (TGFBR)1 and TGFBR2. Surgical outcomes of aortic repair in patients with LDS are poorly known.
METHODS: We enrolled 16 patients with TGFBR mutations identified by gene analysis in this study. Between 1993 and 2011, they underwent 41 aortic surgical procedures. Ten patients (group D: dissection group) underwent aortic repair for acute or chronic aortic dissection as a first surgical intervention, and 6 patients (group N: nondissection group) underwent surgical treatment for aortic root dilatation. The mean follow-up period was 103.7 ± 92.3 months (range, 2- 276 months).
RESULTS: There were no in-hospital deaths. In group N, valve-sparing root replacement (VSRR) was performed in all patients. The residual aorta in 9 patients (90%) from group D required further repairs, 3 times on average. Moreover, in 4 patients (40%), the aorta was entirely replaced in serial procedures. In group N, aortic dissection occurred in only 1 patient (17%). The aortic event-free rates at 5 years were 40% in group D and 80% in group N, respectively (p = 0.819). One late death due to arrhythmia occurred 1 month after VSRR. The cumulative survival rates at 5 years were 100% in group D and 83% in group N, respectively (p = 0.197).
CONCLUSIONS: Surgical outcomes for patients with LDS were satisfactory. Once aortic dissection occurred, the aorta expanded rapidly, requiring further operations. Therefore, early surgical intervention may improve prognosis by preventing a fatal aortic event.
Copyright © 2012 The Society of Thoracic Surgeons. Published by Elsevier Inc. All rights reserved.

Entities:  

Mesh:

Year:  2012        PMID: 22921234     DOI: 10.1016/j.athoracsur.2012.05.111

Source DB:  PubMed          Journal:  Ann Thorac Surg        ISSN: 0003-4975            Impact factor:   4.330


  4 in total

1.  International Registry of Patients Carrying TGFBR1 or TGFBR2 Mutations: Results of the MAC (Montalcino Aortic Consortium).

Authors:  Guillaume Jondeau; Jacques Ropers; Ellen Regalado; Alan Braverman; Arturo Evangelista; Guisela Teixedo; Julie De Backer; Laura Muiño-Mosquera; Sophie Naudion; Cecile Zordan; Takayuki Morisaki; Hiroto Morisaki; Yskert Von Kodolitsch; Sophie Dupuis-Girod; Shaine A Morris; Richmond Jeremy; Sylvie Odent; Leslie C Adès; Madhura Bakshi; Katherine Holman; Scott LeMaire; Olivier Milleron; Maud Langeois; Myrtille Spentchian; Melodie Aubart; Catherine Boileau; Reed Pyeritz; Dianna M Milewicz
Journal:  Circ Cardiovasc Genet       Date:  2016-11-21

2.  Impact of connective tissue disease on the surgical outcomes of aortic dissection in patients with cystic medial necrosis.

Authors:  Toshiki Fujiyoshi; Kenji Minatoya; Yoshihiko Ikeda; Hatsue Ishibashi-Ueda; Takayuki Morisaki; Hiroko Morisaki; Hitoshi Ogino
Journal:  J Cardiothorac Surg       Date:  2017-11-23       Impact factor: 1.637

3.  Surgical Outcome and Histological Differences between Individuals with TGFBR1 and TGFBR2 Mutations in Loeys-Dietz Syndrome.

Authors:  Yoshimasa Seike; Hitoshi Matsuda; Hatsue Ishibashi-Ueda; Hiroko Morisaki; Takayuki Morisaki; Kenji Minatoya; Hitoshi Ogino
Journal:  Ann Thorac Cardiovasc Surg       Date:  2021-01-06       Impact factor: 1.520

4.  Case-matched Comparison of Cardiovascular Outcome in Loeys-Dietz Syndrome versus Marfan Syndrome.

Authors:  Kristina Mühlstädt; Julie De Backer; Yskert von Kodolitsch; Kerstin Kutsche; Laura Muiño Mosquera; Jens Brickwedel; Evaldas Girdauskas; Thomas S Mir; Adrian Mahlmann; Nikolaos Tsilimparis; Axel Staebler; Lauritz Schoof; Heide Seidel; Jürgen Berger; Alexander M Bernhardt; Stefan Blankenberg; Tilo Kölbel; Christian Detter; Katalin Szöcs; Harald Kaemmerer
Journal:  J Clin Med       Date:  2019-11-29       Impact factor: 4.241

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.